← Atlas Theme · spans 1 topics
A stark transatlantic regulatory split leaves patients in one hemisphere stranded without critical therapies.
Differing regulatory risk tolerances and data interpretations between the FDA and European authorities create a geographical divide where patients are denied access to approved treatments.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
Omeros's Narsoplimab (Yartemlea) Faces Negative CHMP Opinion, Highlighting US-EU Regulatory Divide European and American agencies reviewed the identical clinical package for narsoplimab but split entirely, leaving EU transplant patients without a marketed therapeutic option.
Science & Health
Tolebrutinib Wins EU Approval as First nrSPMS Disability-Targeting Therapy Amid Ongoing US Regulatory Stall While European patients gain access to the first therapeutic targeting nrSPMS disability accumulation, the drug remains stalled under FDA review, blocking US patients.